Abstracts tagged "Abatacept"

Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
Takuma Tsuzuki Wada¹, Yu Funakubo Asanuma², Mayumi Matsuda³, Hiroaki Yazawa², Yoshinobu Nakao⁴, Noritsune Kozu⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology, Saga University Hospital, Saga, Japan, ⁵Kozu Orthopedic Clinic, Yachiyo, Japan
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…
Abstract Number: 1716 • 2018 ACR/ARHP Annual Meeting
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
Dinesh Khanna¹ and Cathie Spino², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Biostatistics, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment with CTLA4Ig, abatacept (ABA), in early diffuse cutaneous systemic sclerosis (dcSSc; the Phase 2 ASSETtrial) showed evidence of improvements in modified Rodnan skin…
Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Nicola Ruperto¹, Hermine I. Brunner², Gabriel Vega-Cornejo³, Alberto Berman⁴, Rubén J. Cuttica⁵, Francisco Ávila-Zapata⁶, Michael Henrickson⁷, Daniel J Kingsbury⁸, John F. Bohnsack⁹, Thomas Lutz¹⁰, Nadina E Rubio-Pérez¹¹, Valeria Gerloni¹², Xiaohui Li¹³, Marleen Nys¹⁴, Robert Wong¹³, Alberto Martini¹⁵ and Daniel J Lovell¹⁶, ¹Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁵Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁶Star Medica Hospital, Merida, Yucatán, Mexico, ⁷Cincinnati Children’s Medical Center, Cincinnati, OH, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹University of Utah School of Medicine, Salt Lake City, UT, ¹⁰Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, ¹¹Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, ¹²Istituto Gaetano Pini, Milan, Italy, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…
Abstract Number: 2383 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Frank Weller-Heinemann⁴, Kirsten Minden⁵ and Ariane Klein⁶, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁴Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologics is particularly important in pediatric patients (pts) who may require prolonged treatment. Since 2001, the German Biologics JIA Registry (BIKER)…
Abstract Number: 2485 • 2018 ACR/ARHP Annual Meeting
Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs
Damemarie Paul¹, Laura McDonald¹, Alexander Marshall², Tammy Curtice³, Melissa Lingohr-Smith⁴, Brandy Menges⁴ and Jay Lin⁴, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Novosys Health, Green Brook, NJ
Background/Purpose: Abatacept is a targeted disease-modifying antirheumatic drug (tDMARD) that has demonstrated a lower risk for infection in comparison with other tDMARDs among rheumatoid arthritis…
Abstract Number: 2554 • 2018 ACR/ARHP Annual Meeting
Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
Vibeke Strand¹, Thomas Lehman², Harris A Ahmad², Alyssa Johnsen², Sandhya Balachandar² and Philip J. Mease³, ¹Stanford University, Palo Alto, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: In the randomized, placebo (pbo)-controlled Phase III ASTRAEA study (ClinicalTrials.gov, NCT01860976) patients (pts) with active psoriatic arthritis (PsA) were randomized to abatacept (ABA) or…
Abstract Number: 2745 • 2018 ACR/ARHP Annual Meeting
Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents
Daniela Rossi¹, Irene Cecchi², Elena Rubini³, Massimo Radin⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose: At least 2 biological therapies [tocilizumab (TCZ) and abatacept (ABA)] have been proven to be effective in the management of Giant cell arteritis (GCA)…
Abstract Number: 609 • 2017 ACR/ARHP Annual Meeting
Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial
Iain B. McInnes¹, Gianfranco Ferraccioli², MA D'Agostino³, M Le Bars⁴, S Banerjee⁵, H Ahmad⁵, Y Elbez⁶, J Ye⁵ and Philip J Mease⁷, ¹University of Glasgow, Glasgow, Great Britain, ²Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Hôpital Ambroise Paré, Boulogne-Billancourt, France, ⁴Bristol-Myers Squibb, Rueil-Malmaison, France, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Excelya, Boulogne-Billancourt, France, ⁷Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Obesity is a risk factor for the development and severity of psoriatic arthritis (PsA).1,2 Patients (pts) with increased BMI (overweight/obese) are less likely to…
Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting
Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Yannick Degboé^1,2, Michael Schiff³, Michael Weinblatt⁴, Roy Fleischmann⁵, HA Ahmad⁶ and Arnaud Constantin^2,7, ¹Toulouse University Hospital, Toulouse, France, ²Université Paul Sabatier, Toulouse, France, ³University of Colorado, Denver, CO, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Purpan University Hospital, Toulouse, France
Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…
Abstract Number: 1429 • 2017 ACR/ARHP Annual Meeting
Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials
D Fleming¹, TA Simon¹, A Torbeyns², U Meier-Kriesche¹ and A Johnsen¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Braine l’Alleud, Belgium
Background/Purpose: Patients with RA have a 1.5–2-fold increased risk of mortality compared with the general population. The association between mortality rates and different RA treatments…
Abstract Number: 1468 • 2017 ACR/ARHP Annual Meeting
Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study
Rieke Alten¹, HM Lorenz², X Mariette³, HG Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen, Nürnberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION (NCT02109666) was the first prospective international non-interventional study designed to provide long-term real-world data on abatacept retention in patients (pts) with RA. The…
Abstract Number: 1469 • 2017 ACR/ARHP Annual Meeting
Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept
Rieke Alten¹, H-M Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept in Canada and Europe (NCT02109666). The objective was…
Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting
Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, L Bessette², E Alemao³, B Haraoui⁴, F Massicotte¹, M Mtibaa⁵, E Muratti⁵, Jean-Pierre Pelletier¹, R Postema⁶, Jean-Pierre Raynauld⁷, M-A Rémillard⁸, D Sauvageau¹, A Turcotte⁹, É Villeneuve¹ and L Coupal¹⁰, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁵Bristol-Myers Squibb, Montréal, QC, Canada, ⁶Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁷Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁸Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ¹⁰Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…
Abstract Number: 2272 • 2017 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
Daniel J Lovell¹, N Ruperto², N Tzaribachev³, A Zeft⁴, Rolando Cimaz⁵, V Stanevica⁶, Gerd Horneff⁷, John F. Bohnsack⁸, Thomas A. Griffin⁹, R Carrasco¹⁰, Maria Trachana¹¹, Jason A Dare¹², I Foeldvari¹³, Richard K Vehe¹⁴, TA Simon¹⁵, Hermine I. Brunner¹⁶ and Alberto Martini², ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ³University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ⁴Cleveland Clinic, Cleveland, OH, ⁵Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, ⁶Riga Stradins University, Riga, Latvia, ⁷Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ⁸University of Utah School of Medicine, Salt Lake City, UT, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ¹⁰Specially For Children, Austin, TX, ¹¹Hippokration General Hospital, Thessaloniki, Greece, ¹²University of Arkansas for Medical Sciences, Little Rock, AR, ¹³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Bristol-Myers Squibb, Princeton, NJ, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Abatacept is an FDA- and EMA-approved biologic that is widely used in children with juvenile idiopathic arthritis (JIA). The purpose of this long-term ongoing…
Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry
Leslie R Harrold¹, Heather J. Litman², SE Connolly³, E Alemao³, K Price³, S Kelly³, Sabrina Rebello⁴, W Hua² and Joel Kremer⁵, ¹University of Massachusetts, Worcester, MA, ²Corrona, Southborough, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].